Search Open Mobile Menu

Veracyte® Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 15, 2023-- Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer
View HTML
Toggle Summary Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 11, 2023-- Veracyte, Inc. (Nasdaq: VCYT) outlined the company’s cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank (SVB). As of December 31, 2022 , the company had $178.9 million in cash,
View HTML
Toggle Summary Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 27, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in two upcoming investor conferences.
View HTML
Toggle Summary Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
Grew Fourth Quarter Revenue to $80.3 Million Grew 2022 Total Revenue to $296.5 Million Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 22, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full
View HTML
Toggle Summary Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
- Decipher Prostate test improves risk-stratification to help reduce under- and over-treatment - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 15, 2023-- Veracyte, Inc . (Nasdaq: VCYT) today announced that data published in the International Journal of Radiation Oncology , Biology, Physics
View HTML
Toggle Summary New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment
Additional findings from G-MINOR trial reinforce clinical utility of Veracyte’s Decipher Prostate Genomic Classifier SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 13, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced new data being presented this week at the 2023 American Society of Clinical
View HTML
Toggle Summary Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 6, 2023-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2022 after the close of market on Wednesday, February 22, 2023 . Company management will host a conference call and
View HTML
Toggle Summary Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 1, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced that six abstracts highlighting new data focused on the company’s Decipher urologic cancer testing offerings will be presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium, taking
View HTML
Toggle Summary Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
Findings published in Frontiers in Endocrinology were derived from analyses of Veracyte’s comprehensive thyroid nodule database of whole transcriptome sequencing SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 1, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced that data published in
View HTML
Toggle Summary Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
Meta-analysis of 13 independent studies suggests genomic test performs even better in real-world clinical practice as compared to original clinical validation study SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 15, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced that findings
View HTML